A retrospective study of 70 patients undergoing surgical treatment for adjacent segment disease (ASD) after anterior cervical decompression and fusion (ACDF).
To analyze the risk factors for the development of ASD in patients who underwent ACDF.
ACDF has provided a high rate of clinical success for the cervical degenerative disc disease; nevertheless, adjacent segment degeneration has been reported as a complication at the adjacent level secondary to the rigid fixation.
Between January 2005 and December 2012, 70 consecutive patients underwent surgery for ASD after ACDF in our institution. In all patients thorough clinical and radiological examination was performed preoperatively, postoperatively, and at the final follow-up. The clinical data included the Neck Disability Index (NDI) and the Visual Analogue Scale (VAS). The radiological evaluation included x-rays and magnetic resonance imaging (MRI) for all patients. The duration of follow up after the adjacent segment operation ranged from 3 to 10 years.
Surgery for ASD was performed after a mean period of 32 months from the primary ACDF. ASD occurred after single level ACDF in 54% of cases, most commonly after C5/6 fusion (28%). Risk factors for ASD were found to be preexisting radiological signs of degeneration at the primary surgery (74%) and bad sagittal profile after the primary ACDF (90%).
ASD occurred predominantly in the middle cervical region (C4–6); especially in patients with preexisting evidence of radiological degeneration in the adjacent segment at the time of primary cervical fusion, notably when this surgery failed to restore or maintain the cervical lordosis.
Level of Evidence: 4
∗Department of Spine Surgery, Zentralklinik Bad Berka, Germany
†Department of Orthopedic Surgery, Alexandria University, Egypt.
Address correspondence and reprint requests to Mootaz Shousha, MD, Robert-Koch-Allee 9, 99437 Bad Berka, Germany; E-mail: firstname.lastname@example.org
Received 29 March, 2017
Revised 21 June, 2017
Accepted 2 August, 2017
The device(s)/drug(s) is/are FDA-approved or approved by corresponding national agency for this indication.
No funds were received in support of this work.
No relevant financial activities outside the submitted work.